Up-regulation of PTEN at the transcriptional level is an adverse prognostic factor in female lung adenocarcinomas
- 1 August 2007
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 57 (2) , 201-206
- https://doi.org/10.1016/j.lungcan.2007.03.007
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Health, Labour and Welfare
- Japan Society for the Promotion of Science
- Smoking Research Foundation
- Ministry of Education, Culture, Sports, Science and Technology
- National Institute of Biomedical Innovation
This publication has 21 references indexed in Scilit:
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung CancersJNCI Journal of the National Cancer Institute, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial PrecancersJNCI Journal of the National Cancer Institute, 2000
- Immunohistochemical Evidence of Loss of PTEN Expression in Primary Ductal Adenocarcinomas of the BreastThe American Journal of Pathology, 1999
- Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell linesOncogene, 1998
- PTEN mutations in gliomas and glioneuronal tumorsOncogene, 1998
- Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancersNature Genetics, 1997
- PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate CancerScience, 1997